Gufic Biosciences (509079) Q2 25/26 earnings summary

Executive summary

• Focused execution across hospital injectables, women's health, aesthetics, and surgical platforms, with disciplined expansion in both domestic and international markets.

• Indore facility commenced production in Oct 2024, targeting global regulatory standards and margin accretion by FY27.

• Achieved total revenue of ₹230.4 Cr in Q2 FY26, up from ₹204.2 Cr in Q2 FY25, and ₹457.3 Cr for H1 FY26, up from ₹407 Cr in H1 FY25.

• Standalone and consolidated unaudited financial results for the quarter and half year ended September 30, 2025, were reviewed and approved by the Board and auditors, with no material misstatements identified.

• The business operates in a single segment: Pharmaceuticals.

Financial highlights

• Q2 FY26 revenue was ₹23,041.80 lakhs (standalone), up from ₹20,417.99 lakhs in Q2 FY25; consolidated revenue was ₹23,917.00 lakhs.

• EBITDA for Q2 FY26 was ₹37.9 Cr with a margin of 16.45%, compared to ₹38.7 Cr and 18.95% in Q2 FY25.

• PAT for Q2 FY26 stood at ₹14.9 Cr, down from ₹21.8 Cr in Q2 FY25; H1 FY26 PAT was ₹27 Cr versus ₹42.6 Cr in H1 FY25.

• Basic EPS for H1 FY26 was ₹2.69 (standalone) and ₹2.98 (consolidated), up from ₹2.17 and ₹2.17, respectively, in the prior year period.

• Cash and cash equivalents increased to ₹7,361.17 lakhs (standalone) and ₹7,459.98 lakhs (consolidated) as of September 30, 2025.

Outlook and guidance

• Indore facility expected to reach EBITDA break-even by Q4 FY26 and become margin-accretive by FY27.

• Strategic focus on expanding regulated market presence, scaling CMO, and launching new products in critical care, fertility, and aesthetics.

• International business projected to grow 32-33% YoY, with domestic infertility and botulinum toxin divisions also showing strong growth.

• Pipeline includes innovative launches in contrast media, TPN, and advanced injectables.